¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Acute hepatitis B without delta- agent and without hepatic coma"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
  • hepatic flexure <³ª> f. coli dextra
    ¿ì°áÀå°î(éÓÌ¿ ÍØ) °£¸¸°î(ÊÜØ¶ÍØ) .
  • hepatic flexure <³ª> f. coli dextra
    ¿ì°áÀå°î(¿ì°áÀå°î), °£¸¸°î(°£¸¸°î) .
  • hepatic flexure ³ª f. coli dextra
    ¿ì°áÀå°î(éÓÌ¿ ÍØ) °£¸¸°î(ÊÜØ¶ÍØ) .
  • hepatic glycogen
    °£(ÊÜ)±Û¸®ÄÚ°Õ.
  • hepatic gutter
    °£±¸(ÊÜϵ).
  • hepatic hilum
    °£¹®
  • hepatic infantilism
    °£¼º¼Ò¾ÆÁõ.
  • hepatic insufficiency
    °£(±â´É)ºÎÀü.
  • hepatic lipase
    °£¸®ÆÄÁ¦
  • hepatic lobes
    °£¿±
  • hepatic lobule
    ¸®°£¼Ò¿±(ÊÜá³ç¨).
  • hepatic lobule
    °£¼Ò¿±
  • hepatic lobules
    °£¼Ò¿±
  • hepatic lymph nodes
    ¹æ»ç °£(ÊÜ)¸²ÇÁÀý.
  • hepatic lymph nodes
    °£¸²ÇÁÀý
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
  • hepatic lymph nodes
    °£¸²ÇÁÀý
  • hepatic neoplasm
    °£½Å»ý¹°(ÊÜãæßæÚª).
  • hepatic nevus
    ¸®°£¼º¸ð¹Ý(ÊÜàõÙ½Úè).
  • hepatic part of inferior vena cava
    ¾Æ·¡´ëÁ¤¸Æ°£ºÎºÐ
  • hepatic plate
    °£¼¼Æ÷ÆÇ
  • hepatic plexus
    °£½Å°æ¾ó±â
  • hepatic plexus <³ª> p. hepaticius
    °£½Å°æ¾ó±â, °£½Å°æÃÑ.
  • hepatic plexus <³ª> p. hepaticus
    °£½Å°æÃÑ.
  • hepatic porphyria
    °£¼ºÆ÷¸£ÇǸ®¾Æ.
  • hepatic portal <³ª> porta hepatica
    °£¹® (ÊÜÚ¦).
  • hepatic portal <³ª> porta hepatis
    °£¹® (°£¹®).
  • hepatic portal vein
    °£¹®¸Æ(°£¹®¸Æ).
  • hepatic portal vein
    °£¹®¸Æ(ÊÜÚ¦Øæ).
  • hepatic portal vein
    °£¹®¸Æ
  • hepatic prolylhydroxylase
    °£ÇÁ·Ñ¸±È÷µå·Ï½Ç¶óÁ¦
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 17
FA false aneurysm; Families Anonymous; Fanconi anemia; far advanced; fatty acid; febrile antigen; femor...
GBA ganglionic blocking agent; gingivobuccoaxial
GRA gated radionuclide angiography; glucocorticoid-remedial aldosteronism; gonadotropin-releasing agent
GTA gene transfer agent; Glanzmann thrombasthenia; glycerol teichoic acid
HRLA human reovirus-like agent
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 17
HGP Hepatic glucose production
HNF4 Hepatic nuclear factor 4
HPVG Hepatic portal venous gas
HSC Hepatic stellate cell
H-TGL Hepatic triglyceride lipase
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • acute diverticulitis
    ±Þ¼º °Ô½Ç¿°
  • acute eczema
    ±Þ¼º ½ÀÁø
    µ¿ÀǾî=eczema acutum.
  • acute endocarditis
    ±Þ¼º ½É³»¸·¿°
    ±Þ¼ºÀÇ °æ°ú¸¦ ÃëÇÏ´Â ½É³»¸·¿°, Æó·Å, ¼ö¸·¿°, »ê¿å¿­, ±× ¹ÛÀÇ °¨¿°ÁõÀ¸·Î ÀÕµû¶ó ¹ß»ýÇÏ´Â °æ¿ì°¡ ¸¹´Ù. ¿øÀαÕÀ¸·Î¼­´Â Æ÷µµ»ó ±¸±Õ, ¼ö¸·¿°±Õ, Æó·Å±Õ µîÀÌ ÀÖ´Ù. ½É³»¸·ÀÇ º´º¯Àº °íµµÀÌ°í ÆÇ¸·Á¶Á÷ÀÇ ÆÄ±«°¡ ½ÉÇÏ¸é ÆÇ¸·ÀÇ Ãµ°ø, °Ç»öÀÇ ´Ü¿­À» °¡Á®¿À´Â ¼öµµ ÀÖ´Ù. ÀÓ»óÀûÀ¸·Î´Â ¹ß¿­, ½ÉÀâÀ½, Ç÷ħġ ÃËÁø, ºñÁ¾ µîÀ» º¸°Ô µÈ´Ù. Ç÷¾× ¹è¾çÀÌ Áø´Ü¿¡ Áß¿äÇÏ´Ù. Ä¡·á´Â Æä´Ï½Ç¸° ±× ¹ÛÀÇ Ç×»ýÁ¦¸¦ Åõ¿©ÇÑ´Ù.
  • acute epidemic leukoencephalitis
    ±Þ¼º À¯Ç༺ ¹é ³ú¿°, ±Þ¼º À¯Ç༺ ¹éÁú ³ú¿°
  • acute epididymoorchitis
    ±Þ¼º °íȯ ºÎ°íȯ¿°
  • acute erythematous atrophic candidosis
    ±Þ¼º È«¹Ý¼º À§Ã༺ ĵµð´ÙÁõ
  • acute erythremia
    ±Þ¼º ÀûÇ÷º´
  • acute exacerbation
    ±Þ¼º Áõ¿À
    ¸¸¼º °ñ¼ö¼º ¹éÇ÷º´ÀÇ ¸»±â¿¡ ±Þ¼º ¹éÇ÷º´ »óÅ·Π¾ÇÈ­ÇÏ´Â °Í. ¹éÇ÷º´ ¼¼Æ÷ÀÇ Å¹ÝÀÌ °ñ¼ö¾Æ±¸
  • acute exposure
    ±Þ¼º ÇÇÆø
    ¹æ»ç¼± °Ç°­°ü¸®Çлó »ç¿ëµÇ´Â ¿ë¾îÀÌ°í ¹æ»ç¼± »ç°í µî, ºñ±³Àû ªÀº ½Ã°£¿¡ °íü°¡ ÇÇÆøÇÏ´Â °ÍÀ» ¸»ÇÑ´Ù. Á÷¾÷ÀûÀ¸·Î ¾Æ¹«·¡µµ ÇÇÇÒ ¼ö ¾ø´Â ÇÇÆøÀ̳ª ½ºÆ®·ÐƬÀÇ »À¿¡ ´ëÇÑ Ä§Âø µî Àå¹Ý°¨±âÀÇ ¹æ»ç¼± µ¿À§¿ø¼Ò°¡ ¸ö ¾È¿¡ µé¾î°£ °æ¿ìÀÇ ÇÇÆøÀ» ¸¸¼º ÇÇÆøÀ̶ó°í ¸»Çϴµ¥ ´ëÇØ¼­ À̰°ÀÌ ¸»ÇÑ´Ù.
  • acute febrile neutrophilic dermatosis
    ±Þ¼º ¹ß¿­¼º È£Áß±¸¼º ÇǺο°
  • acute fulminating meningococcemia
    ±Þ¼º Àü°Ý¼º ¼ö¸·±¸±Õ ±ÕÇ÷Áõ
  • acute gangrenous pulpitis
    ±Þ¼º ±«Àú¼º Ä¡¼ö¿°
    Ä¡¼ö°¡ Ç÷¾× °ø±ÞÀÇ Áß´Ü, ¼¼±Õ ħÀÔ¿¡ ÀÇÇÏ¿© ±Þ°ÝÇÏ°Ô ±«»çÇÔÀ¸·Î¼­, È¿¼Ò¼º ´Ü¹éÁú ºÐÇØ¿¡ ÀÇÇÑ ¾ÇÃ븦 ÀÏÀ¸Å°´Â ±Þ¼º ¿°Áõ.
  • acute gastritis
    ±Þ¼º À§¿°
    Á¡¸·ÀÇ ±Þ¼º ¿°Áõ °úÁ¤À¸·Î ´ë°³ Àϰú¼ºÀÌ´Ù. ÀÌ ¿°ÁõÀº Á¡¸·³»¿¡ ÃâÇ÷°ú ½ÉÇÑ °æ¿ì¿¡´Â Ç¥¸é Á¡¸·ÀÇ ¹þ°ÜÁüÀ» ¼ö¹ÝÇÑ´Ù. ÀÌ·¯ÇÑ ½ÉÇÑ ¹Ì¶õÇü ±Þ¼º À§¿°Àº ±Þ¼º À§Àå°ü ÃâÇ÷ÀÇ ÇÑ Áß¿äÇÑ ¿øÀÎÀÌ µÈ´Ù.
  • acute gastrointestinal bleeding
    ±Þ¼º ¼ÒÈ­°ü ÃâÇ÷, ±Þ¼º À§Àå°ü ÃâÇ÷
  • acute glomerulonephritis
    ±Þ¼º »ç±¸Ã¼ ½Å¿°
    ÇüÅÂÇÐÀûÀ¸·Î´Â ±Þ¼º ¹Ì¸¸¼º Áõ½Ä¼º »ç±¸Ã¼½Å¿°À» ÀÏÀ¸Å°°í ÀÓ»óÀûÀ¸·Î´Â Ç÷´¢, °íÁú¼ÒÇ÷Áõ, ÇÌ´¢, °íÇ÷¾Ð µîÀÇ ±Þ¼º ½Å¿° ÁõÈıºÀ» ÁÖ¼Ò·Î ÇÏ´Â ½Å¿°À¸·Î ´Ü¹é´¢ ¹× ºÎÁ¾ µîµµ µ¿¹ÝµÉ ¼ö ÀÖÀ¸³ª ½ÅÁõÈıºº¸´Ù Á¤µµ°¡ ½ÉÇÏÁö ¾ÊÀº °æ¿ì°¡ ´ëºÎºÐÀÌ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
chronic interstitial hepatitis An obsolete term for cirrhosis of the liver.
(05 Mar 2000)
chronic persistent hepatitis <pathology> A form of hepatitis usually caused by hepatitis C or B, that consists of mild persistent liver inflammation.
Often a mild elevation of the liver enzymes will be seen on liver profile or SMAC 25 assay. Liver biopsy indicates persistent hepatitis.
Incidence: 1 in 1,000.
(02 Jan 1998)
chronic persisting hepatitis A form of chronic hepatitis that is usually benign, not progressing to cirrhosis, and usually asymptomatic without physical findings but with continuing abnormalities of tests of liver status.
Synonym: chronic persistent hepatitis.
(05 Mar 2000)
mouse hepatitis A form of hepatitis in mice due to synergism between the mouse hepatitis virus and Eperythrozoon coccoides.
Synonym: murine hepatitis.
(05 Mar 2000)
mouse hepatitis virus A coronavirus, in the family Coronaviridae, that in the presence of Eperythrozoon coccoides causes fatal hepatitis in newly weaned mice; otherwise causes inapparent infection.
(05 Mar 2000)
plasma cell hepatitis <pathology> A type of chronic active hepatitis that results from circulating auto-antibodies and chronic inflammation of the liver.
Symptoms are those of chronic active hepatitis.
(27 Sep 1997)
MS-1 hepatitis A virus disease with a short incubation period (usually 15 to 50 days), caused by hepatitis A virus, a member of the family Picornaviridae, often transmitted by faecal-oral route; may be inapparent, mild, severe, or occasionally fatal and occurs sporadically or in epidemics, commonly in school-age children and young adults; necrosis of periportal liver cells with lymphocytic and plasma cell infiltration is characteristic and jaundice is a common symptom.
Synonym: epidemic hepatitis, hepatitis A, infectious hepatitis, MS-1 hepatitis, short incubation hepatitis, virus A hepatitis.
(05 Mar 2000)
murine hepatitis A form of hepatitis in mice due to synergism between the mouse hepatitis virus and Eperythrozoon coccoides.
Synonym: murine hepatitis.
(05 Mar 2000)
halothane hepatitis Hepatocellular damage said to result from the administration of halothane anaesthesia.
(05 Mar 2000)
hepatitis <pathology> Inflammation of the liver.
(18 Nov 1997)
hepatitis A <virology> A form of viral hepatitis, known as infectious hepatitis, due to its ability to be spread through personal contact with oral secretions or stool. Virus will be shed in the stools of an infected individual 2-3 weeks prior to the onset of any symptoms. Hepatitis A may also be transmitted sexually. Symptoms are similar to those of influenza, but the skin and eyes may become yellow. Recent travel to a third world country is a risk factor. There is no specific treatment but infected individuals should avoid potentially hepatotoxic substances.
The virus is a small (27nm diameter) single stranded RNA virus with some resemblance to enteroviruses such as polio.
(27 Sep 1997)
hepatitis agents, gb Proposed members of the family flaviviridae. Gbv-b causes hepatitis in tamarins and possibly humans, and is the putative aetiological agent of a non-(a-e) hepatitis, gb hepatitis.
(12 Dec 1998)
hepatitis a immunization When immediate protection against hepatitis a (infectious hepatitis) is needed, immunoglobulins are used. Protection is effective only if given within 2 weeks of exposure and lasts but 2-4 months. Immunoglobulins can be used to protect household contacts of someone with acute viral hepatitis and travelers to regions with poor sanitation and high hepatitis a rates, when the traveler has to depart sooner than the vaccines can take effect (about 2 weeks). Travelers can receive the immunoglobulin and vaccine simultaneously and be protected immediately and for longer term. When immediate protection is not needed, hepatitis a vaccines are considered for individuals in high-risk settings, including frequent world travelers, sexually active individuals with multiple partners, homosexual men, individuals using illicit drugs, employees of daycare centres, and certain healthcare workers, and sewage workers. Two hepatitis a vaccines called havrix and vaqta are commercially available in the u.s. Both are highly effective and provide protection even after only one dose. Two doses are recommended for adults and 3 doses for children (under 18 years of age) to provide prolonged protection.
(12 Dec 1998)
hepatitis, alcoholic An acute or chronic degenerative and inflammatory lesion of the liver in the alcoholic which is potentially progressive though sometimes reversible. It does not necessarily include steatosis, fibrosis, or cirrhosis of alcoholics, although it is frequently associated with these conditions. It is characterised by liver cell necrosis, infiltration by polymorphonuclear leukocytes and lymphocytes, and mallory bodies. The morphologic changes of chronic alcoholic hepatitis are not likely to be confused with chronic hepatitis (hepatitis, chronic).
(12 Dec 1998)
hepatitis antibodies Immunoglobulins raised by any form of viral hepatitis; some of these antibodies are used to diagnose the specific kind of hepatitis.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 17
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 17
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 17
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 17
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 17
ÅëÇÕ°Ë»ö ¿Ï·á